Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Protalix BioTherapeutics (PLX) Shares Outstanding (Diluted Average) (2016 - 2025)

Protalix BioTherapeutics (PLX) has 12 years of Shares Outstanding (Diluted Average) data on record, last reported at $76.6 million in Q1 2025.

  • For Q1 2025, Shares Outstanding (Diluted Average) rose 4.9% year-over-year to $76.6 million; the TTM value through Mar 2025 reached $76.6 million, up 4.9%, while the annual FY2022 figure was $48.5 million, 9.81% up from the prior year.
  • Shares Outstanding (Diluted Average) reached $76.6 million in Q1 2025 per PLX's latest filing, up from $73.3 million in the prior quarter.
  • Across five years, Shares Outstanding (Diluted Average) topped out at $78.9 million in Q2 2023 and bottomed at $39.9 million in Q1 2021.
  • Average Shares Outstanding (Diluted Average) over 5 years is $55.7 million, with a median of $48.5 million recorded in 2022.
  • Peak YoY movement for Shares Outstanding (Diluted Average): soared 66.7% in 2023, then decreased 7.08% in 2024.
  • A 5-year view of Shares Outstanding (Diluted Average) shows it stood at $44.1 million in 2021, then grew by 9.81% to $48.5 million in 2022, then soared by 62.77% to $78.9 million in 2023, then dropped by 7.08% to $73.3 million in 2024, then increased by 4.51% to $76.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Shares Outstanding (Diluted Average) were $76.6 million in Q1 2025, $73.3 million in Q2 2024, and $73.0 million in Q1 2024.